Codexis Future Growth
Future criteria checks 1/6
Codexis is forecast to grow earnings and revenue by 51.4% and 14.9% per annum respectively while EPS is expected to grow by 52.5% per annum.
Key information
51.4%
Earnings growth rate
52.5%
EPS growth rate
| Life Sciences earnings growth | 15.8% |
| Revenue growth rate | 14.9% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 22 Apr 2024 |
Recent future growth updates
Recent updates
Codexis, Inc.'s (NASDAQ:CDXS) Shares Leap 56% Yet They're Still Not Telling The Full Story
Dec 20
What Does Codexis, Inc.'s (NASDAQ:CDXS) Share Price Indicate?
Dec 19Is Codexis (NASDAQ:CDXS) In A Good Position To Deliver On Growth Plans?
Nov 15Lacklustre Performance Is Driving Codexis, Inc.'s (NASDAQ:CDXS) Low P/S
Jun 28Calculating The Intrinsic Value Of Codexis, Inc. (NASDAQ:CDXS)
Jun 07At US$3.41, Is It Time To Put Codexis, Inc. (NASDAQ:CDXS) On Your Watch List?
May 09Analysts Just Made A Major Revision To Their Codexis, Inc. (NASDAQ:CDXS) Revenue Forecasts
Feb 27We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn
Feb 25Is Codexis, Inc. (NASDAQ:CDXS) Trading At A 28% Discount?
Nov 05Codexis appoints Kevin Norrett as chief operating officer
Oct 03We Think Codexis (NASDAQ:CDXS) Can Afford To Drive Business Growth
Aug 23Analysts Have Just Cut Their Codexis, Inc. (NASDAQ:CDXS) Revenue Estimates By 10%
Jul 28Codexis: Profitability, Return On Capital Are Persistent Headwinds Looking Ahead
Jul 27Codexis gets new executive chief
Jul 18Are Investors Undervaluing Codexis, Inc. (NASDAQ:CDXS) By 35%?
Jul 06Why Codexis, Inc. (NASDAQ:CDXS) Could Be Worth Watching
May 10Codexis: A Company Rooting Itself In A Blossoming Market
Apr 18We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn
Apr 09Does This Valuation Of Codexis, Inc. (NASDAQ:CDXS) Imply Investors Are Overpaying?
Mar 14Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 84 | -16 | -4 | N/A | 2 |
| 12/31/2025 | 62 | -49 | -54 | N/A | 6 |
| 12/31/2024 | 65 | -46 | -55 | N/A | 7 |
| 12/31/2023 | 70 | -76 | -57 | -53 | N/A |
| 9/30/2023 | 74 | -82 | -41 | -37 | N/A |
| 6/30/2023 | 99 | -57 | -6 | -1 | N/A |
| 3/31/2023 | 116 | -48 | 8 | 13 | N/A |
| 12/31/2022 | 139 | -34 | 3 | 11 | N/A |
| 9/30/2022 | 133 | -31 | -7 | 7 | N/A |
| 6/30/2022 | 135 | -19 | -29 | -13 | N/A |
| 3/31/2022 | 122 | -21 | -35 | -19 | N/A |
| 12/31/2021 | 105 | -21 | -28 | -14 | N/A |
| 9/30/2021 | 101 | -15 | -26 | -16 | N/A |
| 6/30/2021 | 83 | -23 | -26 | -20 | N/A |
| 3/31/2021 | 72 | -25 | -27 | -21 | N/A |
| 12/31/2020 | 69 | -24 | -20 | -16 | N/A |
| 9/30/2020 | 67 | -21 | -21 | -19 | N/A |
| 6/30/2020 | 70 | -14 | -20 | -16 | N/A |
| 3/31/2020 | 68 | -14 | -15 | -11 | N/A |
| 12/31/2019 | 68 | -12 | -16 | -13 | N/A |
| 9/30/2019 | 66 | -12 | -14 | -10 | N/A |
| 6/30/2019 | 61 | -14 | -12 | -10 | N/A |
| 3/31/2019 | 62 | -11 | -16 | -13 | N/A |
| 12/31/2018 | 61 | -11 | -17 | -14 | N/A |
| 9/30/2018 | 66 | -9 | -8 | -6 | N/A |
| 6/30/2018 | 59 | -18 | -11 | -9 | N/A |
| 3/31/2018 | 56 | -20 | -10 | -9 | N/A |
| 12/31/2017 | 50 | -23 | -10 | -9 | N/A |
| 9/30/2017 | 38 | -29 | N/A | -12 | N/A |
| 6/30/2017 | 43 | -18 | N/A | -14 | N/A |
| 3/31/2017 | 49 | -9 | N/A | -6 | N/A |
| 12/31/2016 | 49 | -9 | N/A | -2 | N/A |
| 9/30/2016 | 50 | -5 | N/A | 0 | N/A |
| 6/30/2016 | 53 | -1 | N/A | 8 | N/A |
| 3/31/2016 | 43 | -9 | N/A | 4 | N/A |
| 12/31/2015 | 42 | -8 | N/A | 0 | N/A |
| 9/30/2015 | 44 | -5 | N/A | -3 | N/A |
| 6/30/2015 | 34 | -15 | N/A | -1 | N/A |
| 3/31/2015 | 35 | -18 | N/A | -1 | N/A |
| 12/31/2014 | 35 | -19 | N/A | 0 | N/A |
| 9/30/2014 | 31 | -29 | N/A | -9 | N/A |
| 6/30/2014 | 27 | -34 | N/A | -19 | N/A |
| 3/31/2014 | 28 | -38 | N/A | -22 | N/A |
| 12/31/2013 | 32 | -41 | N/A | -23 | N/A |
| 9/30/2013 | 30 | -47 | N/A | -24 | N/A |
| 6/30/2013 | 53 | -40 | N/A | -19 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CDXS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CDXS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CDXS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CDXS's revenue (14.9% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: CDXS's revenue (14.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CDXS's Return on Equity is forecast to be high in 3 years time